Division/Center of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310005, China.
The Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, Hangzhou, 310005, China.
Eur J Med Res. 2024 Sep 2;29(1):448. doi: 10.1186/s40001-024-02042-9.
NUP98 rearrangements (NUP98-r) are rare but overrepresented mutations in pediatric acute myeloid leukemia (AML) patients. NUP98-r is often associated with chemotherapy resistance and a particularly poor prognosis. Therefore, characterizing pediatric AML with NUP98-r to identify aberrations is critically important.
Here, we retrospectively analyzed the clinicopathological features, genomic and transcriptomic landscapes, treatments, and outcomes of pediatric patients with AML.
Nine patients with NUP98-r mutations were identified in our cohort of 142 patients. Ten mutated genes were detected in patients with NUP98-r. The frequency of FLT3-ITD mutations differed significantly between the groups harboring NUP98-r and those without NUP98-r (P = 0.035). Unsupervised hierarchical clustering via RNA sequencing data from 21 AML patients revealed that NUP98-r samples clustered together, strongly suggesting a distinct subtype. Compared with that in the non-NUP98-r fusion and no fusion groups, CMAHP expression was significantly upregulated in the NUP98-r samples (P < 0.001 and P = 0.001, respectively). Multivariate Cox regression analyses demonstrated that patients harboring NUP98-r (P < 0.001) and WT1 mutations (P = 0.030) had worse relapse-free survival, and patients harboring NUP98-r (P < 0.008) presented lower overall survival.
These investigations contribute to the understanding of the molecular characteristics, risk stratification, and prognostic evaluation of pediatric AML patients.
NUP98 重排(NUP98-r)在儿科急性髓系白血病(AML)患者中是罕见但过度表达的突变。NUP98-r 常与化疗耐药和预后特别差相关。因此,对具有 NUP98-r 的儿科 AML 进行特征分析以确定异常情况至关重要。
在此,我们回顾性分析了我们队列中 142 例 AML 患儿的临床病理特征、基因组和转录组图谱、治疗方法和结局。
在我们的队列中,确定了 9 例具有 NUP98-r 突变的患者。在 NUP98-r 患者中检测到 10 个突变基因。在携带 NUP98-r 和不携带 NUP98-r 的患者中,FLT3-ITD 突变的频率有显著差异(P=0.035)。对 21 例 AML 患者的 RNA 测序数据进行无监督层次聚类分析显示,NUP98-r 样本聚类在一起,强烈提示存在一个独特的亚型。与非 NUP98-r 融合和无融合组相比,NUP98-r 样本中 CMAHP 的表达显著上调(P<0.001 和 P=0.001)。多变量 Cox 回归分析表明,携带 NUP98-r(P<0.001)和 WT1 突变(P=0.030)的患者无复发生存期更差,携带 NUP98-r(P<0.008)的患者总生存期更低。
这些研究有助于了解儿科 AML 患者的分子特征、风险分层和预后评估。